The year 2019 saw two novel antidepressants receive FDA approval amid a series of disappointing phase III trials.
NeuroSens recently posted a survey on sequencing disease-modifying therapies (DMTs) in multiple sclerosis to investigate whether clinicians’ approaches have changed in the past 2-3 years. The current survey was a follow-up to a series of surveys conducted over a one-year period ending in December 2017 that accompanied an 8-part article on sequencing. (For a summary of those results see Are opinions changing on changing therapies in MS?, NeuroSens, October 22, 2019). Read More
A researcher in Japan has raised a seasonally timely question: what if Santa Claus had a communicable disease as he made his rounds (Furuse Y. Med J Aust 2019;211:523-524)?
Three drugs for use in neurology or psychiatry have filed with Health Canada and are expected to be approved in 2020. All have received FDA approval in the U.S. Here is a summary of what is waiting in the wings. Read More